Targeted temperature management (TTM) is a medical treatment in which a patient’s body temperature is deliberately lowered or carefully controlled to protect the brain after a life-threatening event like cardiac arrest or oxygen deprivation at birth. The core idea is simple: cooling the body slows brain metabolism by roughly 5 to 7 percent for every degree Celsius the temperature drops, giving injured brain cells more time to recover. TTM is one of the few interventions proven to improve neurological outcomes after the heart stops and is restarted.
How Cooling Protects the Brain
When blood flow to the brain is interrupted, even briefly, a cascade of damaging processes begins. Cells swell, toxic byproducts accumulate, and the brain’s own inflammatory response can destroy tissue that might otherwise survive. Lowering body temperature slows all of these processes at once.
Specifically, cooling reduces the production of harmful molecules called free radicals, decreases brain swelling by lowering blood flow demands, and prevents a type of programmed cell death that damaged neurons trigger in neighboring healthy cells. It also reduces levels of glutamate, a chemical that overexcites brain cells during injury and accelerates damage. The combined effect is a wider window of time for the brain to stabilize before permanent injury sets in.
Who Receives TTM
The most common use of TTM is in adults who have been resuscitated after cardiac arrest. Current American Heart Association guidelines recommend active temperature control for at least 36 hours in adult patients who remain unresponsive after their heart has been restarted. This applies whether the cardiac arrest happened in or out of a hospital.
TTM is also a standard treatment for newborns who experienced oxygen deprivation during birth, a condition called hypoxic-ischemic encephalopathy. Babies born at 35 weeks or later who show signs of brain injury, such as seizures, abnormal muscle tone, or poor reflexes, along with blood tests indicating severe oxygen deprivation, are candidates for cooling. Treatment must begin within six hours of birth and is typically maintained for 72 hours. For newborns, the target temperature is slightly higher than for adults, around 33.5°C measured internally.
TTM has also been studied in severe traumatic brain injury, where longer cooling periods may help control dangerous increases in pressure inside the skull.
The Three Phases of Treatment
TTM unfolds in three distinct phases, each with its own goals and risks.
Induction is the initial cooling period. The goal is to bring core body temperature down to the target range, typically 32 to 34°C (about 90 to 93°F), within four hours of the heart being restarted. Medical teams use various cooling methods during this phase, from simple ice packs and cold fluid infusions to advanced devices like surface cooling pads or specialized catheters inserted into a large vein.
Maintenance keeps the patient at the target temperature for at least 24 hours. Precise control matters here. Even small fluctuations can undermine the protective effects or introduce new risks. Throughout this phase, the medical team closely monitors heart rhythm, blood chemistry, and neurological signs.
Rewarming is arguably the most delicate phase. The body is brought back to normal temperature very slowly, no faster than about one-third of a degree Celsius per hour. Rewarming too quickly can trigger dangerous shifts in blood chemistry. Potassium, for example, moves back out of cells during rewarming, and a sudden spike can cause life-threatening heart rhythm problems. To prevent this, medical teams keep potassium levels slightly lower than normal during the cooling phase so there is a buffer when rewarming begins.
Cooling Methods and Equipment
There are two broad categories of cooling technology. Surface cooling uses external devices placed against the skin: gel-coated pads connected to a temperature-controlled water system, cold air blankets, or even basic setups involving ice packs and fans. Endovascular cooling uses a catheter placed in a large blood vessel, typically in the thigh, which circulates cooled fluid internally.
Both approaches can achieve and maintain target temperatures. Advanced systems offer tighter temperature control with less hands-on adjustment, but studies comparing endovascular and surface methods have not shown a clear survival advantage for one over the other. In practice, the choice often depends on what equipment a hospital has available and the clinical team’s experience. Throughout treatment, core temperature is continuously tracked using internal probes placed in the bladder or esophagus, which give more accurate readings than skin thermometers.
What the Evidence Shows
The landmark trials that established TTM as a standard of care were published in 2002. The HACA trial, a large European study, found that patients cooled to 32 to 34°C after cardiac arrest had a six-month mortality rate of 41 percent compared with 55 percent in the group that received standard care. More strikingly, 55 percent of cooled patients recovered with good neurological function versus 39 percent who were not cooled. A simultaneous Australian trial by Bernard and colleagues found similar results: 49 percent of cooled patients were discharged with a good neurological outcome compared with 26 percent of those treated at normal temperature.
Later trials complicated the picture. The TTM1 trial in 2013 compared cooling to 33°C versus 36°C and found no significant difference in survival or neurological outcomes between the two groups. The TTM2 trial in 2021 went further, comparing 33°C cooling against simply preventing fever (keeping temperature at or below 37.5°C). Again, six-month mortality was nearly identical: 50 percent in the cooled group and 48 percent in the fever-prevention group.
These results shifted the conversation. The current understanding, reflected in the 2025 AHA guidelines, is that actively controlling temperature matters, but cooling to 33°C may not be clearly better than simply preventing fever. The guidelines leave room for either a hypothermic target (32 to 34°C) or a normothermic target (36 to 37.5°C), with a minimum of 36 hours of active temperature management either way. One exception: in patients with cardiac arrest from a non-shockable rhythm, the HYPERION trial found that cooling to 33°C nearly doubled the rate of favorable neurological recovery (10.2 percent versus 5.7 percent), suggesting colder targets may still benefit specific patient populations.
Risks and Side Effects
Cooling the body is not without consequences. Shivering is one of the most immediate challenges. The body naturally fights temperature reduction, and shivering increases metabolic demand, which directly counteracts the point of cooling. Medical teams use sedation and other medications to suppress this response.
Infection risk rises because cooling suppresses the immune system. Heart rhythm disturbances can occur, particularly slower heart rates, though these are usually manageable. Blood clotting is also affected, so patients with active uncontrolled bleeding are generally not candidates for TTM.
The rewarming phase carries its own set of risks. Beyond potassium shifts, rewarming too quickly can cause rebound brain swelling or a spike in fever that overshoots normal body temperature. This rebound hyperthermia can worsen the very brain injury TTM was meant to prevent, which is why the process is kept extremely gradual and temperature monitoring continues well after the target has been reached.
What Recovery Looks Like
TTM is not a cure. It is a protective measure that gives the brain its best chance of recovery after a severe injury. Even with optimal cooling, outcomes after cardiac arrest remain sobering. Roughly half of patients who receive TTM after out-of-hospital cardiac arrest do not survive to six months, and among survivors, the degree of neurological recovery varies widely.
For newborns treated for birth-related oxygen deprivation, outcomes tend to be more encouraging. The NICHD trial demonstrated that whole-body cooling reduced the combined rate of death and disability in eligible newborns, and cooling within six hours of birth is now considered standard care in neonatal intensive care units worldwide. Neurological assessments continue for months and years after treatment, since the full extent of recovery or impairment in infants often only becomes clear as they reach developmental milestones.